Small molecule · Inhibitor of histone deacetylase · developed by Recursion Pharmaceuticals
REC-2282 is an orally available phenylbutyrate-derived small molecule that inhibits histone deacetylase (HDAC) catalytic activity. This leads to chromatin histone hyperacetylation, altered gene expression and induction of tumor cell apoptosis. It is being studied in neurofibromatosis type 2.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05130866 | Phase 2/3 | Neurofibromatosis Type 2 | Terminated | RXRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Neurofibromatosis Type 2
Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.
See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RXRX catalysts and pipeline →